Table 1.
Demographic and clinical data of patients in analysis.
| Total | Group1 |
Group2 |
Group3 |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 197 | Low (101) | High (96) | p value | Low (83) | High (114) | p value | Low (117) | High (80) | p value | |
| Sex | 0.578 | 0.104 | 0.299 | |||||||
| Female | 27 (13.7%) | 12 (6.1%) | 15 (7.6%) | 7 (3.6%) | 20 (10.2%) | 19 (9.6%) | 8 (4.1%) | |||
| Male | 170 (86.3%) | 89 (45.2%) | 81 (41.1%) | 76 (38.6%) | 94 (47.7%) | 98 (49.7%) | 72 (36.5%) | |||
| Age | 64.17±11.05 | 64.89±10.76 | 63.41±11.41 | 0.348 | 65.02±11.14 | 63.54±11.04 | 0.356 | 63.91±10.89 | 64.55±11.41 | 0.690 |
| BMI | 23.65±3.04 | 23.75±3.16 | 23.54±2.94 | 0.641 | 23.9±2.68 | 23.46±3.29 | 0.323 | 23.53±2.87 | 23.82±3.29 | 0.521 |
| Smoker | 0.820 | 0.637 | 0.836 | |||||||
| No | 140 (71.1%) | 73 (37.1%) | 67 (34%) | 57 (28.9%) | 83 (42.1%) | 82 (41.6%) | 58 (29.4%) | |||
| Yes | 57 (28.9%) | 28 (14.2%) | 29 (14.7%) | 26 (13.2%) | 31 (15.7%) | 35 (17.8%) | 22 (11.2%) | |||
| Gross hematuria | 1.000 | 0.455 | ||||||||
| No | 46 (23.4%) | 24 (12.2%) | 22 (11.2%) | 20 (10.2%) | 26 (13.2%) | 30 (15.2%) | 16 (8.1%) | |||
| Yes | 151 (76.6%) | 77 (39.1%) | 74 (37.6%) | 63 (32%) | 88 (44.7%) | 87 (44.2%) | 64 (32.5%) | |||
| Hypertension | 0.035 | 0.164 | ||||||||
| No | 140 (71.1%) | 79 (40.1%) | 61 (31%) | 63 (32%) | 77 (39.1%) | 88 (44.7%) | 52 (26.4%) | |||
| Yes | 57 (28.9%) | 22 (11.2%) | 35 (17.8%) | 20 (10.2%) | 37 (18.8%) | 29 (14.7%) | 28 (14.2%) | |||
| Diabetes | 0.770 | 0.654 | 0.248 | |||||||
| No | 172 (87.3%) | 87 (44.2%) | 85 (43.1%) | 74 (37.6%) | 98 (49.7%) | 99 (50.3%) | 73 (37.1%) | |||
| Yes | 25 (12.7%) | 14 (7.1%) | 11 (5.6%) | 9 (4.6%) | 16 (8.1%) | 18 (9.1%) | 7 (3.6%) | |||
| Tumor size | 0.586 | 0.263 | ||||||||
| ≤3 cm | 110 (55.8%) | 54 (27.4%) | 56 (28.4%) | 50 (25.4%) | 60 (30.5%) | 61 (31%) | 49 (24.9%) | |||
| >3 cm | 87 (44.2%) | 47 (23.9%) | 40 (20.3%) | 33 (16.8%) | 54 (27.4%) | 56 (28.4%) | 31 (15.7%) | |||
| Tumor number | 0.456 | 0.215 | 0.027 | |||||||
| Single | 86 (43.7%) | 41 (20.8%) | 45 (22.8%) | 41 (20.8%) | 45 (22.8%) | 43 (21.8%) | 43 (21.8%) | |||
| Multiple | 111 (56.3%) | 60 (30.5%) | 51 (25.9%) | 42 (21.3%) | 69 (35%) | 74 (37.6%) | 37 (18.8%) | |||
| WHO grade | 0.590 | 0.957 | ||||||||
| Low | 55 (27.9%) | 26 (13.2%) | 29 (14.7%) | 23 (11.7%) | 32 (16.2%) | 32 (16.2%) | 23 (11.7%) | |||
| High | 142 (72.1%) | 75 (38.1%) | 67 (34%) | 60 (30.5%) | 82 (41.6%) | 85 (43.1%) | 57 (28.9%) | |||
| CIS | 0.770 | 0.084 | 1.000 | |||||||
| No | 182 (92.4%) | 87 (44.2%) | 85 (43.1%) | 73 (37.1%) | 109 (55.3%) | 108 (54.8%) | 74 (37.6%) | |||
| Yes | 15 (7.6%) | 14 (7.1%) | 11 (5.6%) | 10 (5.1%) | 5 (2.5%) | 9 (4.6%) | 6 (3%) | |||
| T stage | 0.020 | 1.000 | 0.248 | |||||||
| Ta | 40 (20.3%) | 27 (13.7%) | 12 (6.1%) | 16 (8.1%) | 23 (11.7%) | 26 (13.2%) | 13 (6.6%) | |||
| T1 | 157 (79.7%) | 74 (37.6%) | 84 (42.6%) | 67 (34%) | 91 (46.2%) | 91 (46.2%) | 67 (34%) | |||
| Histology | 0.441 | 0.535 | 0.207 | |||||||
| PTCC | 171 (86.8%) | 90 (45.7%) | 81 (41.1%) | 74 (37.6%) | 97 (49.2%) | 105 (53.3%) | 66 (33.5%) | |||
| HV | 26 (13.2%) | 11 (5.6%) | 15 (7.6%) | 9 (4.6%) | 17 (8.6%) | 12 (6.1%) | 14 (7.1%) | |||
| Recurrence | 0.009 | 1.000 | ||||||||
| No | 112 (56.9%) | 67 (34%) | 45 (22.8%) | 57 (28.9%) | 55 (27.9%) | 67 (34%) | 45 (22.8%) | |||
| Yes | 85 (43.1%) | 34 (17.3%) | 51 (25.9%) | 26 (13.2%) | 59 (29.9%) | 50 (25.4%) | 35 (17.8%) | |||
| Progression | 0.070 | 0.957 | ||||||||
| No | 142 (72.1%) | 79 (40.1%) | 63 (32%) | 69 (35%) | 73 (37.1%) | 85 (43.1%) | 57 (28.9%) | |||
| Yes | 55 (27.9%) | 22 (11.2%) | 33 (16.8%) | 14 (7.1%) | 41 (20.8%) | 32 (16.2%) | 23 (11.7%) | |||
| Risk group | 0.375 | 0.861 | 0.396 | |||||||
| Intermediate | 62 (31.4%) | 34 (33.7%) | 28 (29.2%) | 26 (31.3%) | 36 (31.6%) | 38 (32.5%) | 24 (30%) | |||
| High | 114 (57.9%) | 54 (53.5%) | 60 (62.5%) | 47 (56.6%) | 67 (58.8%) | 64 (54.7%) | 50 (62.5%) | |||
| Very high | 21 (21.6%) | 13 (12.9%) | 8 (8.3%) | 10 (12.0%) | 11 (9.6%) | 15 (12.8%) | 6 (7.5%) | |||
CIS, carcinoma in situ.